Docket Number:12A-990402
Inventor:Yuh-Shan Jou, Yi-Wei Wang
IP Status:TW pending、US pending
Abstract:
This invention relates to identification of novel oncogenic ALK point mutations in lung adenocarcinoma patients. We have shown that these oncogenic ALK mutations activate ALK signaling pathways and result in enhancement of various tumorigenic effects. Treatments of ALK inhibitors to mutation-carried mice have not only shrunk tumor, suppressed metastasis but also significantly improved survival in mice. Oncogenic ALK mutations are therapeutic index of lung cancer. We also demonstrate that phosphorylation of Y1604-ALK is up-regulated early and continued throughout the lung cancer progression in majority of lung cancer patients. The up-regulated phosphor-Y1604 ALK could serve as a diagnostic marker for early detection of lung cancer.
Fields of Application:
Lung cancer is the most common cause of cancer-related mortality accounted for >1.4 million deaths worldwide annually. Patients with ALK fusion (EML4/ ALK) in lung cancer and ALK point mutations in neuroblastoma are likely to response to the ALK inhibitor (ex. Crizotinib). Many pharmaceutical companies are developing ALK inhibitors due to its huge market value. Crizotinib is the first fast track priority drug development for therapy of NSCLC approved by FDA at Aug 26, 2011. The hyperphosphorylation of Y1604-ALK could be developed as early diagnostic marker for lung cancer.
Advantages when compared to the existing technologies:
Our new findings of ALK point mutations and aberrant hyperphosphorylation could serve as target for diagnostic and therapeutic interventions in lung cancer. Since only patients with ALK fusions/mutations are likely to respond to ALK inhibitors, accurate diagnostic screening is essential before prescribing ALK-targeted drugs in lung cancer.
Contact Person:Mei-Fang Lee / 886-2-2787-2503 / mflee@gate.sinica.edu.tw
